A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

Inclusion Criteria: * The subjects voluntarily participated in the study and signed the informed consent. * Male and female aged between 18 and 65 years old , regardless of gender. * Male weight ≥50 kg, female weight ≥45 kg, body mass index (BMI) in the range of (19-30) kg/m2 (including 19 and 30), and no central obesity (waist circumference \<90 cm for men, waist circumference \<85 cm for women); * Patients diagnosed as "hyperuricemia" according to The Chinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout (2019), namely, patients whose blood uric acid level exceeds 480 μmol/L twice on other days, and no clinical symptoms related to hyperuricemia such as arthritis; * Agree to use effective contraceptive methods (including but not limited to abstinence, physical or hormonal contraception, but not hormonal contraception during the study) from signing the informed consent form until 6 months after the infusion of the study drug; * The subjects can attend the interview on time and complete the interview content. Exclusion Criteria: * People who have a history of gout and are using or have used other medications to control uric acid levels in the last 3 months, Asymptomatic hyperuricemia patients who stopped taking uricate-lowering drugs for more than 3 months were excluded. * Secondary hyperuricemia (such as kidney disease, blood system disease, tumor chemotherapy or drug induced). * Urolithiasis, or renal, ureteral calculi, urate crystal deposition indi…